Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies
Study Details
Study Description
Brief Summary
The primary purpose of this study is to determine the safety and efficacy of novel autologous CAR-T cells in patients with hematopoietic and lymphoid malignancies.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Detailed Description
Chimeric antigen receptor (CAR)-modified T cells targeted CD19 have demonstrated unprecedented successes. Besides CD19, many other molecules such as CD123, BCMA, and CD7 may be potential in developing the corresponding CAR-T cells to treat patients with hematopoietic and lymphoid malignancies. UTC Therapeutics Inc. have developed an efficient platform for constructing CAR-T cells that can remodel of tumor microenvironment and enhance the anti-tumor immune response and persistence of CAR-T cells. In this study, all eligible subjects will receive a conditioning chemotherapy regimen of fludarabine and cyclophosphamide followed by investigational treatment, CAR-T cells. Safety, efficacy, pharmacokinetic, and pharmacodynamic of the CAR-T cells will be assessed.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Autologous CAR-T cells A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, CAR-T cells. CAR-T cells targeted CD19/BCMA/CD123/CD7 are autologous genetically modified T cells. |
Biological: Autologous CAR-T cells
CAR-T cells will be infused intravenously.
Drug: Fludarabine
Administered according to package insert
Other Names:
Drug: Cyclophosphamide
Administered according to package insert
Other Names:
|
Outcome Measures
Primary Outcome Measures
- TEAEs [4 weeks]
Incidence and severity of Treatment Emergent Adverse Event.
- TRAEs [4 weeks]
Incidence and severity of Treatment Related Adverse Events.
- AESIs [4 weeks]
Incidence and severity of AEs of Special Interest.
Secondary Outcome Measures
- Duration of Overall Response (DOR) [12 months]
Time from documentation of disease response to disease progression.
- Progression-Free Survival (PFS) [12 months]
PFS was defined as the time from CAR-T infusion to the date of disease progression or death from any cause. Participants not meeting the criteria for progression by the analysis data cutoff date were censored at their last evaluable disease assessment date.
- Overall survival (OS) [12 months]
OS was defined as the time from CAR-T infusion to the date of death. Participants who did not die by the analysis data cutoff date were censored at their last contact date.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Ability to understand and the willingness to sign informed consent.
-
Patients with relapsed or refractory Acute Myeloid Leukemia (AML), B-cell Non-Hodgkin's Lymphoma (B-NHL), Multiple Myeloma (MM), Adult T-cell Leukemia/Lymphoma (ATL), B-cell Acute Lymphoblastic Leukemia (B-ALL) after at least two cycles of first-line therapy or autologous hematopoietic stem cell transplantation (auto-HSCT).
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0~2.
-
Adequate organ functions:
-
Sufficient bone marrow function evaluated by investigator to receive lymphodepleting preparative regimen;
-
Serum creatinine (Cr) ≤ 1.5 × upper limit of normal (ULN), or creatinine clearance rate (as estimated by Cockcroft Gault) > 30 mL/min/1.73 m^2;
-
Alanine aminotransferase (ALT) ≤ 5×ULN; and total bilirubin (TBIL) <2.0mg/dL; TBIL of patients with Gilbert's Syndrome or liver involvement must less than 3.0 mg/dL;
-
Left ventricular ejection fraction (LVEF) > 40%.
- Subjects who have previously received CD19 targeted therapy must have biopsy-proven lymphoma lesions still express CD19 antigen.
Exclusion Criteria:
-
Lymphomas involving only the central nervous system (CNS) (subjects with secondary CNS lymphomas are admitted).
-
History of another malignancy that has not been in remission for at least 2 year (the following conditions may be excluded from the 2-year restriction: non-melanoma skin cancer, completely resected stage I tumor with low probability of recurrence, limited-stage prostate cancer after treatment, biopsy-proven cervical carcinoma in situ, or PAP smear showing squamous epithelium internal lesions).
-
History of treatment with Alemtuzumab within 6 months prior to leukapheresis, or Fludarabine or Cladribine within 3 months prior to leukapheresis.
-
Active hepatitis C (HCV), hepatitis B (HBV), human immunodeficiency virus (HIV), or syphilis infection.
-
Uncontrolled fungal, bacterial, viral, or other infection.
-
Acute or chronic graft-versus-host disease (GVHD).
-
History of any of the following cardiovascular diseases within the past 6 months: Class III or IV heart failure as defined by the New York Heart Association (NYHA), cardiac angioplasty or stent, myocardial infarction, unstable angina, or other clinically significant heart disease.
-
History or clinical evidence of CNS disease.
-
Female subjects who are pregnant or lactating.
-
Prior CAR-T therapy or other genetically modified T cell therapy.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Shanghai Pudong Hospital, Fudan University Affiliated Pudong Medical Center | Shanghai | Shanghai | China | 201399 |
Sponsors and Collaborators
- Shanghai Pudong Hospital
- UTC Therapeutics Inc.
Investigators
- Principal Investigator: Zhiguo Long, Shanghai Pudong Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2020-IIT-002-E03